These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 16110641)
21. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon. Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796 [TBL] [Abstract][Full Text] [Related]
22. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy. Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754 [No Abstract] [Full Text] [Related]
23. Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil? Andersen MH; Gehl J; Reker S; Geertsen P; Becker JC; thor Stratem P J Clin Oncol; 2005 Aug; 23(22):5265-7; author reply 5267-8. PubMed ID: 16051975 [No Abstract] [Full Text] [Related]
24. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Weber JS Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797 [No Abstract] [Full Text] [Related]
25. Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Reisfeld RA Pigment Cell Res; 1992; Suppl 2():109-12. PubMed ID: 1409412 [No Abstract] [Full Text] [Related]
26. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]
27. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570 [TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Honsik CJ; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017 [TBL] [Abstract][Full Text] [Related]
29. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Irie RF; Morton DL Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8694-8. PubMed ID: 3464977 [TBL] [Abstract][Full Text] [Related]
30. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Foon KA; Lutzky J; Baral RN; Yannelli JR; Hutchins L; Teitelbaum A; Kashala OL; Das R; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M J Clin Oncol; 2000 Jan; 18(2):376-84. PubMed ID: 10637253 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. Oldham RK; Foon KA; Morgan AC; Woodhouse CS; Schroff RW; Abrams PG; Fer M; Schoenberger CS; Farrell M; Kimball E J Clin Oncol; 1984 Nov; 2(11):1235-44. PubMed ID: 6333489 [TBL] [Abstract][Full Text] [Related]
32. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Magnani JL; Brockhaus M; Smith DF; Ginsburg V; Blaszczyk M; Mitchell KF; Steplewski Z; Koprowski H Science; 1981 Apr; 212(4490):55-6. PubMed ID: 7209516 [TBL] [Abstract][Full Text] [Related]
33. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Hellström I; Brankovan V; Hellström KE Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1499-502. PubMed ID: 3856277 [TBL] [Abstract][Full Text] [Related]
34. Boronated monoclonal antibody 225.28S for potential use in neutron capture therapy of malignant melanoma. Tamat SR; Moore DE; Patwardhan A; Hersey P Pigment Cell Res; 1989; 2(4):278-80. PubMed ID: 2798319 [TBL] [Abstract][Full Text] [Related]